Trial Identifier: | D133FR00169 |
Sponsor: | AstraZeneca |
NCTID:: | NCT04808050 |
Start Date: | November 2021 |
Primary Completion Date: | October 2022 |
Study Completion Date: | October 2022 |
Condition: | Lung Cancer |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
No documents have been posted yet.
Country | Location |
---|---|
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |
Hong Kong, Hong Kong | Hong Kong, Hong Kong |